Page last updated: 2024-08-24

topotecan and ter 286

topotecan has been researched along with ter 286 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, G; del Campo, J; Finkler, N; Hunter, J; Jones, M; Kavanagh, J; Kaye, S; Lohr, A; Matei, D; Meng, L; Vergote, I; Vermorken, JB	1

Trials

1 trial(s) available for topotecan and ter 286

Article	Year
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome	2009

Article

Year

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:13

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome

2009